Celltrion launches AVTOZMA subcutaneous formulation in US
March 17, 2026 | 12:29
The South Korean biopharmaceutical company began commercial distribution of its tocilizumab biosimilar self-injection product in the American market.
Celltrion secures FDA nod for STEQEYMA® pediatric dosing
June 16, 2025 | 13:00
The approval of a new presentation enhances treatment flexibility for children with inflammatory diseases.
Celltrion presents post hoc analysis of LIBERTY studies of ZYMFENTRA® at the American College of Gastroenterology 2024 Annual Scientific Meeting
October 30, 2024 | 02:25
Celltrion USA today announced a late-breaking post hoc analysis of the pivotal LIBERTY studies of ZYMFENTRA®, during the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting.
Mobile Version